Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06400303 · ClinicalTrials.gov registry record · Phase 1
KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis
A Phase 1 study of Systemic Sclerosis and Systemic Sclerosis - Diffuse Cutaneous, sponsored by Kyverna Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
- 2
- Study locations
NCT06400303: Active Phase 1 study of Systemic Sclerosis and Systemic Sclerosis - Diffuse Cutaneous, sponsored by Kyverna Therapeutics.
NCT06400303 is a Phase 1 study of Systemic Sclerosis and Systemic Sclerosis - Diffuse Cutaneous that is active but no longer recruiting, run by Kyverna Therapeutics. The registered enrollment target is 3 participants, below the 279-participant average among 26 other Systemic Sclerosis trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06400303, a Phase 1 study of Systemic Sclerosis and Systemic Sclerosis - Diffuse Cutaneous, is active but no longer recruiting, sponsored by Kyverna Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
- 2
- Study locations
Study Summary
A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects with Systemic Sclerosis
Conditions Studied
Interventions
- DRUG Standard lymphodepletion regimen
- BIOLOGICAL KYV-101
Study Locations (2)
California
- Stanford University Medical Center - Palo Alto
New York
- Northwell Health - Great Neck
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2024-08-06 |
| Est. Completion | 2027-03 |
| Phase | Phase 1 |
What the registry record for NCT06400303 still lists
NCT06400303 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 279-participant average among 26 other Systemic Sclerosis trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Systemic Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Standard lymphodepletion regimen is the first listed.
NCT06400303 reports a single indexed study location in California, New York.
Frequently Asked Questions
What is clinical trial NCT06400303 about?
NCT06400303 is a clinical study titled "KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis". A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects with Systemic Sclerosis
What is the current status of trial NCT06400303?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2024-08-06. Estimated completion is 2027-03.
What conditions does trial NCT06400303 study?
This clinical trial studies the following conditions: Systemic Sclerosis, Systemic Sclerosis - Diffuse Cutaneous, Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria.
What interventions are being tested in trial NCT06400303?
The interventions under investigation include: Standard lymphodepletion regimen (DRUG), KYV-101 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06400303?
This trial is sponsored by Kyverna Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06400303 being conducted?
This trial has 2 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06400303's enrollment target sits among peer trials
3 27th of 26 the lowest of 26 other Systemic Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Systemic Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
RECRUITING · Phase 1
-
A Study of AZD0120 in Autoimmune Diseases
RECRUITING · Phase 1
-
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
RECRUITING · Phase 1
-
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
RECRUITING · Phase 1
-
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI